Information Provided By:
Fly News Breaks for August 7, 2019
Aug 7, 2019 | 07:44 EDT
Barclays analyst Balaji Prasad raised his price target for Jazz Pharmaceuticals to $180 from $164 saying Xyrem outperformed Q2 while Sunosi "looks promising" and the pipeline expands. The analyst has a "strong" outlook for Jazz's sleep franchise and keeps an Overweight rating on the shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ